Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fecal microbial transplantation (FMT) provides to replace beneficial bacteria with more favorable microbiomes in recipient with dysbiosis. The aim of the present study was to prospectively investigate the efficacy of FMT by assessing the clinical and endoscopic response in patients with ulcerative colitis (UC) who had failed anti-inflammatory and immunosuppressive therapy. METHODS: In this prospective and uncontrolled study, 30 patients with UC were included. All medications except mesalazine were stopped 4 weeks before FMT. Colonoscopy was performed both before and after FMT. To assess the efficacy of FMT, Mayo scores were calculated at week 0 and week 12. A total of 500 mL extracted fresh fecal suspension was administered into the 30 to 40 cm proximal of terminal ileum of recipients. RESULTS: After FMT, 21 of the (70%) 30 patients showed clinical response, and 13 of the 30 (43.3%) patients achieved clinical and endoscopic remission at the week 12. Nine patients (30%) were accepted as a nonresponder at the end of the week 12. There was no significant difference among donors concerning both the rate of clinical remission and clinical response. No adverse events were observed in the majority of patients during FMT and 12 weeks follow-up. Seven patients (23.3%) experienced mild adverse events such as nausea, vomiting, abdominal pain, diarrhea, and fewer after FMT. CONCLUSION: FMT could be considered as a promising rescue treatment modality before surgery in patients with refractory UC. Besides, FMT also appears to be definitely safer and more tolerable than the immunosuppressive therapy in patients with UC (NCT02575040).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789 · cited 4×
“Success of fecal microbial transplantation (FMT) with an overall cure rate of over 80% in treatment of refractory or recurrent Clostridium difficile infection (CDI) led to draw the attention of authors for intestinal diseases including IBD.”
BackgroundInfluentialMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 2×
“Moayyedi et al[7] and Paramsothy et al[8] showed that the rate of clinical remission in patients who received FMT was higher than placebo.”
BackgroundRossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 2×
“In contrast, Rossen et al([9]) were not able to demonstrate a significant difference in the rate of clinical remission between the FMT and placebo groups.”
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Colman, R. J., & Rubin, D. T. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.006 · Cited by 475
Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235 · cited 1×
“Clinical studies have shown that several changes in phylum level of gut microbiota composition, including a decrease of Firmicutes and Bacteriodetes and a concomitant increase of Proteobacteria and Actinobacteria, are related to UC.([12]) However, it is still debated whether these changes are responsible for activatio…”
BackgroundCui, B., Li, P., Xu, L., Zhao, Y., Wang, H., Peng, Z., Xu, H., Xiang, J., He, Z., Zhang, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0646-2 · Cited by 148 · cited 2×
“Cui et al[16] reported that step-up FMT strategy could lead to steroid-free clinical improvement or remission in patients with steroid-dependent UC.”
Background
Research works printed but not linked: 18
- Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI · Paper page
- Serban, 2015, Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet?, Nutr Clin Pract, 30, 760, 10.1177/0884533615606898 · DOI · Paper page
- Danese, 2011, Ulcerative colitis, N Engl J Med, 365, 1713, 10.1056/NEJMra1102942 · DOI · Paper page
- Girotra, 2016, Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes, Dig Dis Sci, 61, 3007, 10.1007/s10620-016-4229-8 · DOI
- Paramsothy, 2016, Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial, J Crohns Colitis, 10, S14
- Silverberg, 2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, 5A, 10.1155/2005/269076 · DOI · Paper page
- Cammarota, 2016, Principles of DNA-based gut microbiota assessment and therapeutic efficacy of fecal microbiota transplantation in gastrointestinal diseases, Dig Dis, 34, 279, 10.1159/000443362 · DOI · Paper page
- Britton, 2014, Role of the intestinal microbiota in resistance to colonization by Clostridium difficile, Gastroenterology, 146, 1547, 10.1053/j.gastro.2014.01.059 · DOI · Paper page
- Sun, 2016, Fecal microbiota transplantation as a novel therapy for ulcerative colitis: a systematic review and meta-analysis, Medicine (Baltimore, 95, e3765, 10.1097/MD.0000000000003765 · DOI
- Shi, 2016, Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis, PLoS One, 11, e0157259, 10.1371/journal.pone.0157259 · DOI · Paper page
- Scaldaferri, 2016, Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis, Transplant Proc, 48, 402, 10.1016/j.transproceed.2015.12.040 · DOI
- Kump, 2016, Any future for fecal microbiota transplantation as treatment strategy for inflammatory bowel diseases?, Dig Dis, 34, 74, 10.1159/000447379 · DOI
- Xu, 2016, Clinical efficacy maintains patients’ positive attitudes toward fecal microbiota transplantation, Medicine (Baltimore, 95, e4055, 10.1097/MD.0000000000004055 · DOI
- Damman, 2015, Low level engraftment and improvement following a single colonoscopic administration of fecal microbiotato patients with ulcerative colitis, PLoS One, 10, e0133925, 10.1371/journal.pone.0133925 · DOI · Paper page
- Kahn, 2013, Patient perceptions of fecal microbiota transplantation for ulcerative colitis, Inflamm Bowel Dis, 19, 1506, 10.1097/MIB.0b013e318281f520 · DOI · Paper page
- Zhang, 2016, Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis, PLoS One, 11, e0158227, 10.1371/journal.pone.0158227 · DOI · Paper page
- Peyrin-Biroulet, 2014, Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial, Gut, 63, 88, 10.1136/gutjnl-2013-304984 · DOI · Paper page
- Reinisch, 2012, C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I, Aliment Pharmacol Ther, 35, 568, 10.1111/j.1365-2036.2011.04987.x · DOI · Paper page
Cited by
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Microbiota transplantation: Concept, methodology and strategy for its modernization
FMT-standardization Study Group, Zhang, F., Cui, B., He, X., Nie, Y., Wu, K., & Fan, D. (2018) · Protein & Cell · doi:10.1007/s13238-018-0541-8 · Cited by 300
Microbiome as a therapeutic target in alcohol-related liver disease
Sarin, S. K., Pande, A., & Schnabl, B. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.019 · Cited by 253
Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression
Trzeciak, P., & Herbet, M. (2021) · Nutrients · doi:10.3390/nu13030927 · Cited by 139
Rees, N. P., Shaheen, W., Quince, C., Tselepis, C., Horniblow, R. D., Sharma, N., Beggs, A. D., Iqbal, T. H., & Quraishi, M. N. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104088 · Cited by 73
Metadata
- Authors
- Uygun, A., Ozturk, K., Demirci, H., Oger, C., Avci, I. Y., Turker, T., & Gulsen, M.
- Venue
- Medicine
- Published
- 2017-04
- Volume
- 96
- Issue
- 16
- Pages
- e6479
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2606047789
- Cited by
- 58
- References
- 8
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. https://app.cochat.ai/papers/10.1097/md.0000000000006479
- The paper
- Uygun, A., Ozturk, K., Demirci, H., Oger, C., Avci, I. Y., Turker, T., & Gulsen, M. (2017). Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. Medicine. https://doi.org/10.1097/md.0000000000006479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.